These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2818675)

  • 1. Pharmacokinetic study of cefodizime in experimentally infected animals.
    Arai S; Tabata S; Kobayashi S; Inazu M; Hayashi S
    Arzneimittelforschung; 1989 Aug; 39(8):877-82. PubMed ID: 2818675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Laboratory and clinical investigations of cefodizime in infectious diseases in childhood].
    Komada Y; Arai S; Kamiya H; Sakurai M; Shimizu S; Nishi H; Inoue M; Kojima M; Kawaguchi H; Yoshizumi T
    Jpn J Antibiot; 1989 Jun; 42(6):1346-57. PubMed ID: 2795858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on cefodizime, a new cephem antibiotic, in the field of pediatrics].
    Sato H; Narita A; Matsumoto K; Nakazawa S; Suzuki H; Nakanishi Y; Niino K; Nakazawa S
    Jpn J Antibiot; 1989 Jun; 42(6):1306-21. PubMed ID: 2795855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Laboratory and clinical studies on cefodizime in the pediatric field].
    Yanagishima M; Yanai M; Yanagi T; Tsuji Y; Imamura H; Nakayama N
    Jpn J Antibiot; 1989 Jun; 42(6):1424-35. PubMed ID: 2795866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cefodizime on chemokines of liver tissues in mice with immunological hepatic injury.
    Wang P; Kan QC; Yu ZJ; Li L; Pan X
    Chin Med J (Engl); 2011 Mar; 124(5):746-50. PubMed ID: 21518570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacokinetics of cefodizime in critically ill elderly patients.
    Meyer B; Traunmueller F; Bojic A; Locker G; Schmid R; Winkler S; Thalhammer F
    Int J Antimicrob Agents; 2006 Apr; 27(4):335-8. PubMed ID: 16563704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical studies of cefodizime in the pediatric field].
    Niino M; Kida K; Matsuda H; Murase M
    Jpn J Antibiot; 1989 Jun; 42(6):1400-13. PubMed ID: 2795864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefodizime once daily in the treatment of lower respiratory tract infections.
    Piovano CF; Palombini BC; Dagrosa EE; Mendoza F; Facco EB
    Arzneimittelforschung; 1997 May; 47(5):674-7. PubMed ID: 9205786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of cefotiam in the treatment of bacterial infections].
    Mussini C; Zanni G; Braglia MP
    Clin Ter; 1984 Dec; 111(5):401-9. PubMed ID: 6097395
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical evaluation of ceftriaxone.
    File TM; Tan JS; Salstrom SJ
    Clin Ther; 1984; 6(5):653-61. PubMed ID: 6090021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing time and sex-related differences in the pharmacokinetics of cefodizime and in the circadian cortisol rhythm.
    Jonkman JH; Reinberg A; Oosterhuis B; de Noord OE; Kerkhof FA; Motohashi Y; Levi F; Dammacco F; Carandente F
    Chronobiologia; 1988; 15(1-2):89-102. PubMed ID: 3416675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP technical report on the toxicity studies of Cupric Sulfate (CAS No. 7758-99-8) Administered in Drinking Water and Feed to F344/N Rats and B6C3F1 Mice.
    Hebert C
    Toxic Rep Ser; 1993 Jul; 29():1-D3. PubMed ID: 12209195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Brogden RN
    Drugs; 1992 Nov; 44(5):800-34. PubMed ID: 1280568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo activity of cefodizime.
    Shah PM; Knothe H
    Infection; 1992; 20 Suppl 1():S9-13. PubMed ID: 1526686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue distribution and disposition kinetics of enrofloxacin in healthy and E. coli infected broilers.
    Soliman GA
    Dtsch Tierarztl Wochenschr; 2000 Jan; 107(1):23-7. PubMed ID: 10689795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the clinical activity of cefotiam (SCE 963). Multicentric study in 7 centers].
    Bryskier A; Humbert G; Borsa F; Bertrand A; Janbon F; Lafaix C; Beucler A; Veyssier P; Dusehu E; Modai J
    Pathol Biol (Paris); 1983 May; 31(5):328-35. PubMed ID: 6312392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation and immunomodulatory study of cefodizime].
    Li G; Zhang Y; Ji M
    Zhonghua Nei Ke Za Zhi; 1997 Nov; 36(11):759-63. PubMed ID: 10451950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.